MP101
AXP000236.1 · Phage therapy
- Platform
- phage product (non-engineered)
- Originator
- MicrobiotiX
- Sponsor
- MicrobiotiX
Names
| Name | Type | Source |
|---|---|---|
| MP101 | preferred name, code | curator, ctgov |
Virus
- Role
- Phage
- Family
- Caudoviricetes
- Virus
- Pseudomonas aeruginosa bacteriophage
- Replication
- replicating
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (7)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07492771 | MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia | Recruiting | Phase 1 | 2026-07-25 | 2026-12 | 18 | Pneumonia - Bacterial; Pseudomonas Aeruginosa Infection |
| NCT04922918 | Ligilactobacillus Salivarius MP101 for Elderly in a Nursing Home | Unknown | 2020-10-01 | 2021-06-24 | 25 | Covid19 | |
| NCT03044249 | A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression | Terminated | Phase 2 | 2017-05-04 | 2020-01-30 | 81 | Aggression; Agitation; Alzheimer Dementia; Dementia; Psychosis |
| NCT02246816 | A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001 | Withdrawn | Phase 3 | 2015-02 | 2018-02 | 0 | SBS; Short Bowel Syndrome; Short Gut; Short Gut Syndrome |
| NCT02242656 | A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals | Withdrawn | Phase 3 | 2014-12 | 2017-12 | 0 | SBS; Short Bowel; Short Bowel Syndrome; Short Gut; Short Gut Syndrome |
| NCT00449254 | Phase 2a Randomized, Double-Blind Study of Oleoyl-Estrone in Male Morbidly Obese Adults | Unknown | Phase 2 | 2006-10 | 24 | Obesity | |
| NCT00449202 | Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101) | Unknown | Phase 2 | 2006-06 | 100 | Obesity |
Recent changes
No changes recorded in its trials yet.
Clinical papers
No confirmed clinical papers yet.
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 36552791 | Pharmacological Profile of MP-101, a Novel Non-racemic Mixture of R- and S-dimiracetam with Increased Potency in Rat Models of Cognition, Depression and Neuropathic Pain. | Cells | 2022 | name in title: MP101 |
| PMID 36590434 | Administration of Ligilactobacillus salivarius CECT 30632 to elderly during the COVID-19 pandemic: Nasal and fecal metataxonomic analysis and fatty acid profiling. | Frontiers in microbiology | 2022 | name in abstract: MP101 |
| PMID 34574259 | Administration of Ligilactobacillus salivarius MP101 in an Elderly Nursing Home during the COVID-19 Pandemic: Immunological and Nutritional Impact. | Foods (Basel, Switzerland) | 2021 | name in title: MP101 |
| PMID 31585135 | Disease modifying mitochondrial uncouplers, MP101, and a slow release ProDrug, MP201, in models of Multiple Sclerosis. | Neurochemistry international | 2019 | name in title: MP101 |
| PMID 18312263 | The CBS subdomain of inosine 5'-monophosphate dehydrogenase regulates purine nucleotide turnover. | Molecular microbiology | 2008 | name in abstract: MP101 |
| PMID 12701147 | Novel escherichia coli strain allows efficient recombinant protein production using lactose as inducer. | Biotechnology and bioengineering | 2003 | name in abstract: MP101 |
Notes
Anti-Pseudomonas aeruginosa phage product in a phase 1 trial in acute P. aeruginosa pneumonia (NCT07492771).
How to cite
MP101 (AXP000236.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000236.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.